We also demonstrated that wild‐type rice‐based O‐TMab and P‐TMab inhibited the proliferation of HER2+ breast tumour cells by blocking HER2 signalling (Figure 5 and Figure S3). Here, ERBB2 is linked to breast neoplasm.